Erin E Crotty, MD
Cancer and Blood Disorders Center, Brain Tumor Program, Immunotherapy Program
On staff since July 2020
Children's Title: Attending Physician, Pediatric Hematology/Oncology and Bone Marrow Transplant
Academic Title: Assistant Professor, Department of Pediatrics, University of Washington School of Medicine
Research Title: Principal Investigator, Ben Towne Center for Childhood Cancer Research
Research Center: Ben Towne Center for Childhood Cancer Research
"I’m motivated by the connections I make with each patient and committed to improving their daily experience living with and beyond a cancer diagnosis. I believe excellence in oncology care is built on team science, and I’m privileged to work with an incredible multidisciplinary team in Seattle, where translating discoveries from the lab bench to the patient is a familiar reality."
-
Erin Crotty, M.D. is an attending physician and pediatric oncologist in the Brain Tumor Program at Seattle Children's Hospital and Assistant Professor at the University of Washington School of Medicine. She cares for children and adolescents with brain and spinal cord tumors, and is the medical lead for the Retinoblastoma Program alongside oncologic ophthalmologist, Andrew Stacey, M.D. She is involved locally and internationally in early phase clinical trials for children with brain tumors and serves as site Principal Investigator for the Pacific Pediatric Neuro-oncology Consortium (PNOC). Her research and clinical interests focus on implementing new immunotherapies, like CAR T cells, and precision medicine approaches for difficult-to-treat brain tumors.
Dr. Crotty completed her pediatric residency training at Children's National Medical Center in Washington, D.C. and returned home to the west coast for her hematology/oncology fellowship at Seattle Children's Hospital/University of Washington, where she completed additional translational research training in the laboratory of James Olson, M.D.,Ph.D. at the Fred Hutchinson Cancer Research Center, studying novel protein therapeutics.
-
Related Pages
-
The Olson lab identifies, prioritizes, and advances therapeutics into clinical trials for children with brain cancer, with increasing focus on types of brain tumors that are uncommon and have the greatest need for translational research.
-
Learn about treatment options for retinoblastoma, cancer in the lining of the eye. At Seattle Children’s, your child will get care from a team of specialists experienced in treating retinoblastoma. We provide the most advanced treatments in our region, including intra-arterial chemotherapy.
-
-
-
Dr. Crotty is an incredible doctor who treats not only our son, but our entire family, with the utmost care and respect. She became our primary oncologist shortly after joining Seattle Children's brain tumor team and I could not believe we got so lucky to be connected with her when our son was diagnosed with brain cancer. She has helped us navigate the most difficult conversations and decisions with expert information, thorough explanation, and so much compassion. I couldn't recommend Dr. Crotty more for her expertise and caring nature.
-
-
Award Name Award Description Awarded By Award Date 2022 Emerging Scientist Award Children's Cancer Research Fund Oct. 2022 - Oct. 2023 Clinical Scholars Research Program Seattle Children's Research Institute Oct. 2021 - Oct. 2023 NIH Loan Repayment Award, Pediatric Extramural 2021 The Childhood Brain Tumor Foundation (CBTF) Research Award 2020 Resident Teaching Award Children's National Medial Center 2015 - 2017 Gill Fellowship Research Award George Washington University 2011 -
Other Publications
-
Crotty E, Gust JPediatric ependymoma: New perspectives on older trials.
35325202 Neuro-oncology, 2022 Jun 1 : 24(6)949-950 PMCID:PMC9159413 -
Ohlsen TJD, Scanlon S, Perez FA, Ermoian RP, Paulson VA, Hauptman JS, Crotty EE, Ting MASynchronous rare tumors in a pediatric patient with a de novo cancer predisposition syndrome.
35484874 Pediatric blood & cancer, 2022 Apr 28 : e29746 -
Mustafi D, Waligorski N, Paulson V, Cole B, Crotty EE, Stacey AWPineoblastoma Without Retinal Tumors in a Patient With a Mosaic Retinoblastoma Pathogenic Variant.
35297960 JAMA ophthalmology, 2022 Apr 1 : 140(4)437-439 -
Scherpelz KP, Crotty EE, Paulson VA, Lockwood CM, Leary SES, Ellenbogen RG, Lee A, Ermoian RP, Vitanza NA, Cole BLTwo cases of pineal anlage tumor with molecular analysis.
35129878 Pediatric blood & cancer, 2022 April : 69(4)e29596 -
Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JMMedulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival.
33963961 Journal of neuro-oncology, 2021 June : 153(2)225-237 PMCID:PMC8248272 -
Crotty E, Downey K, Ferrerosa L, Flores C, Hegde B, Raskin S, Hwang E, Vitanza N, Okada HConsiderations when treating high-grade pediatric glioma patients with immunotherapy.
33225764 Expert review of neurotherapeutics, 2021 Feb. : 21(2)205-219 PMCID:PMC7880880 -
Crotty EE, Leary SES, Geyer JR, Olson JM, Millard NE, Sato AA, Ermoian RP, Cole BL, Lockwood CM, Paulson VA, Browd SR, Ellenbogen RG, Hauptman JS, Lee A, Ojemann JG, Vitanza NAChildren with DIPG and high-grade glioma treated with temozolomide, irinotecan, and bevacizumab: the Seattle Children's Hospital experience.
32556862 Journal of neuro-oncology, 2020 July : 148(3)607-617 -
Crumm CE, Crotty EE, Albert CM, Blair AB, Otjen JP, Feldman KWAtraumatic Spinal Epidural Hematoma as Initial Presentation of Hemophilia A in an Infant.
30870339 Pediatric emergency care, 2019 Mar 12 -
Crotty EE, Meier ER, Wells EM, Hwang EI, Packer RJAnaplastic Ependymoma in a Child With Sickle Cell Anemia: A Case Report Highlighting Treatment Challenges for Young Children With Central Nervous System Tumors and Underlying Vasculopathy.
26488903 Pediatric blood & cancer, 2016 March : 63(3)547-50
-
-
Grant Title Grantor Amount Award Date 2022 Emerging Scientist Award Children's Cancer Research Fund 2022 - 2023 Clinical Research Scholars Program (CRSP) Award Center for Clinical and Translational Research Oct. 2021 - Oct. 2023 The Childhood Brain Tumor Foundation Research Grant The Childhood Brain Tumor Foundation July 2020 - July 2022 NIH 5T32CA009351 Ruth L. Kirschstein Research Service Award NIH July 2018 - July 2020
Overview
- Board Certification(s)
-
Pediatric Hematology-Oncology
Pediatrics
- Medical/Professional School
-
George Washington University School of Medicine & Health Sciences, Washington, DC
- Residency
-
Children's National Medical Center, Washington, DC
- Fellowship
-
University of Washington School of Medicine GME, Seattle, WA
- Clinical Interests
-
Brain and spinal cord tumors of childhood; high-grade glioma (HGG), diffuse intrinsic pontine glioma (DIPG); diffuse midline glioma (DMG); medulloblastoma, ependymoma, CAR T cell immunotherapy; early phase clinical trials; Retinoblastoma
- Research Description
-
Dr. Crotty's research interests include immuno-oncology and precision medicine approaches for children with brain and spinal cord tumors. Dr. Crotty is particularly interested in the translation of promising therapies from the lab bench into innovative clinical trials for patients. She collaborates with international cancer consortium members in the design and implementation of clinical research.
Dr. Crotty's prior work in the Olson Laboratory at the Fred Hutchinson Cancer Center (now located at Seattle Children's Research Institute) studying novel immunotherapy for medulloblastoma provided the preclinical foundation for an upcoming international CONNECT Phase I clinical trial, which she will lead as co-Principal Investigator. In 2022, she was awarded the Children's Cancer Research Fund Emerging Scientist Award to study a novel cell-free DNA sequencing technique to reliably detect residual disease left over after treatment in the cerebrospinal fluid (CSF). For children with brain tumors, this platform could enable personalized treatment with reduced toxicity.
- Research Focus Area
-
Early phase clinical trials for pediatric brain tumors, Cancer biology, Immunotherapy, CAR-T cells, Epigenetic modifying agents, cell-free DNA